XBI145.88 −3.10%IBB207.98 −2.13%S&P 5007,416.59 −1.92%NASDAQ 10027,197.15 −2.67%DOW 3051,608.17 −1.41%FTSE 10010,803.40 −0.72%
Biotech Today Subscribe

Biotechnology Today · AI in Healthcare

Evogene Targets Acute GVHD With AI-Designed Drug Series

Evogene is advancing AI-designed molecules for steroid-refractory acute GVHD toward studies needed before human testing, targeting a severe transplant complication.

Anil Deshpande · 3 min read
Evogene Targets Acute GVHD With AI-Designed Drug Series

Key facts

  • Company: Evogene Ltd. (NASDAQ: EVGN)
  • Intended patients: Steroid-refractory acute graft-versus-host disease
  • Discovery platform: ChemPass AI explored more than 110 billion virtual molecules
  • Development stage: Lead series advancing toward IND-enabling studies

Evogene selected acute graft-versus-host disease for its internal drug discovery program after using ChemPass AI to explore more than 110 billion virtual molecules.

Evogene Ltd. (NASDAQ: EVGN) has selected acute graft-versus-host disease as the target for its internal drug discovery program, putting a severe transplant complication at the center of its effort to develop proprietary medicines using artificial intelligence.

The company announced the indication on Oct. 28, 2026, and said its lead series is advancing toward investigational new drug, or IND, enabling studies—the work needed to support an application to begin human testing. The immediate development task is therefore to turn promising molecular properties into a package suitable for clinical development, rather than establish a treatment benefit already demonstrated in patients.

A treatment gap after steroids fail

Acute graft-versus-host disease, or aGVHD, is a potentially life-threatening complication of hematopoietic stem cell transplantation. Evogene cited estimates that it affects approximately 30%–40% of transplant recipients and that mortality among patients whose disease does not respond to steroids can reach 50%.

That steroid-refractory population is the intended focus of the program. According to the company's announcement carried by PR Newswire, ruxolitinib is the only approved second-line therapy, leaving a need for additional approaches when initial steroid treatment fails.

Evogene is pursuing a potential first-in-class small molecule aimed at a signaling pathway associated with severe inflammation. Robert Zeiser, head of tumor immunology at University Medical Center Freiburg and an adviser to the program, said the research identified a pathway that is highly overactive in steroid-refractory disease.

Evogene is pursuing a potential first-in-class small molecule aimed at a signaling pathway associated with severe inflammation.

The clinical proposition depends on more than suppressing that pathway. A candidate would also need to be tolerable in the transplant patients it is intended to help. Potency and selectivity are relevant starting points, but they do not by themselves establish patient safety or improved outcomes.

AI discovery moves toward a development test

Evogene said its ChemPass AI platform explored a virtual chemical space containing more than 110 billion molecules. Within several months, the company began generating a series of candidates with new chemical structures designed to be feasible to synthesize.

The company described the candidates as active at nanomolar concentrations, selective for their target and favorable on absorption, distribution, metabolism and excretion, collectively known as ADME, as well as toxicology. These are company-reported discovery findings; their relevance to treatment will depend on subsequent development.

The platform is intended to optimize several drug properties simultaneously rather than identify activity alone. That makes preservation of the reported combination—potency, selectivity and drug-handling characteristics—a central test as Evogene advances its lead series toward IND-enabling work.

Corey Cutler, director of the adult stem cell transplantation program at Dana-Farber Cancer Institute, is advising alongside Zeiser on target selection and development strategy. Their involvement brings clinical and translational expertise to a program still at the molecule-development stage.

Evogene describes the unmet need as a multibillion-dollar market opportunity. For now, that is a commercial ambition attached to an early discovery program: the company is building an internally owned therapeutic asset, while the work ahead must establish whether its designed molecules can support human testing and ultimately benefit steroid-refractory patients.

Sources

Photo: Edward Jenner · Pexels Licence — source

Filed under Biotechnology Today AI in Healthcare

The Biotech Today briefing

Trials, approvals and the deals moving biotech, in your inbox. Free.

Unsubscribe from any email. See our privacy policy.